Search Within

Isabelle C Riviere

  1. "Xiuyan Wang"
  2. "Yongzeng Wang"
  3. "Jae Park"
Formats
  1. Meeting Abstract (9)
  2. Journal Article (7)
Groups
  1. Adult Leukemia (16)
  2. Center for Hematologic Malignancies (16)
  3. Department of Medicine (16)
  4. GSK Faculty (16)
  5. Hematologic Malignancies Research (16)
  6. Hematologic Malignancies, Division of (16)

More Groups

People
  1. Jae Park (16)
  2. Renier Brentjens (16)
  3. Xiuyan Wang (16)
  4. Yongzeng Wang (16)
  5. Michel Sadelain (13)
  6. Brigitte Senechal (12)

More People

Years
  1. 2021 (1)
  2. 2019 (2)
  3. 2018 (3)
  4. 2017 (7)
  5. 2015 (2)
  6. 2014 (1)
Publications
  1. Blood (4)
  2. Journal of Clinical Oncology (3)
  3. Haematologica (2)
  4. Molecular Therapy (2)
  5. JCI Insight (1)
  6. Leukemia and Lymphoma (1)

More Publications

Publishers
  1. American Society of Hematology (4)
  2. American Society of Clinical Oncology (3)
  3. Nature Publishing Group (3)
  4. Ferrata Storti Foundation (2)
  5. Amer Soc Clinical Investigation Inc (1)
  6. American Association for the Advancement of Science (1)

More Publishers

Results (16)

Export to EndNote / Excel | PubMed

Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Depletion of high-content CD14(+) cells from apheresis products is critical for successful transduction and expansion of CAR T cells during large-scale cGMP manufacturing
    Journal Article

    Wang, X.; Borquez-Ojeda, O.; Stefanski, J.; Du, F.; Qu, J.; Chaudhari, J.; Thummar, K.; Zhu, M.; Shen, L. B.; Hall, M.; more...
    Molecular Therapy - Methods & Clinical Development (2021)

    Fulltext@MSK | Save
  • CD19 CAR T cells following autologous transplantation in poor-risk relapsed and refractory B-cell non-Hodgkin lymphoma
    Journal Article

    Sauter, C. S.; Senechal, B.; Rivière, I.; Ni, A.; Bernal, Y.; Wang, X.; Purdon, T.; Hall, M.; Singh, A. N.; Szenes, V. Z.; more...
    Blood (2019)

    Fulltext@MSK | Save
  • Safety and tolerability of conditioning chemotherapy followed by CD19-targeted CAR T cells for relapsed/refractory CLL
    Journal Article

    Geyer, M. B.; Riviere, I.; Senechal, B.; Wang, X.; Wang, Y.; Purdon, T. J.; Hsu, M.; Devlin, S. M.; Palomba, M. L.; Halton, E.; more...
    JCI Insight (2019)

    Fulltext@MSK | Save
  • Autologous CD19-Targeted CAR T cells in patients with residual CLL following initial purine analog-based therapy
    Journal Article

    Geyer, M. B.; Rivière, I.; Sénéchal, B.; Wang, X.; Wang, Y.; Purdon, T. J.; Hsu, M.; Devlin, S. M.; Halton, E.; Lamanna, N.; more...
    Molecular Therapy (2018)

    Fulltext@MSK | Save
  • Concurrent therapy of chronic lymphocytic leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia utilizing CD19-targeted CAR T-cells
    Journal Article

    Geyer, M. B.; Manjunath, S. H.; Evans, A. G.; Park, J. H.; Davila, M. L.; Cutler, C. S.; Wang, X.; Wang, Y.; Senechal, B.; Rivière, I.; more...
    Leukemia and Lymphoma (2018)

    Fulltext@MSK | Save
  • Long-term follow-up of CD19 CAR therapy in acute lymphoblastic leukemia
    Journal Article

    Park, J. H.; Rivière, I.; Gonen, M.; Wang, X.; Sénéchal, B.; Curran, K. J.; Sauter, C.; Wang, Y.; Santomasso, B.; Mead, E.; more...
    New England Journal of Medicine (2018)

    Fulltext@MSK | Save
  • A phase I trial of CD19-targeted EGFRt/19-28z/4-1BBL armored chimeric antigen receptor (CAR) modified T cells in patients with relapsed or refractory chronic lymphocytic leukemia
    Meeting Abstract

    Park, J. H.; Riviere, I.; Wang, X.; Senechal, B.; Bernal, Y.; Halton, E.; Diamonte, C.; Wang, Y.; Brentjens, R. J.; Sadelain, M.
    Journal of Clinical Oncology (2017)

    Fulltext@MSK | Save
  • Durable long-term survival of adult patients with relapsed B-ALL after CD19 CAR (19-28z) T-cell therapy
    Meeting Abstract

    Park, J. H.; Riviere, I.; Wang, X.; Senechal, B.; Wang, Y.; Mead, E.; Santomasso, B.; Halton, E.; Diamonte, C.; Bernal, Y.; more...
    Journal of Clinical Oncology (2017)

    Fulltext@MSK | Save
  • Baseline and early post-treatment clinical and laboratory factors associated with severe neurotoxicity following 19-28z CAR T cells in adult patients with relapsed B-ALL
    Meeting Abstract

    Park, J. H.; Santomasso, B.; Riviere, I.; Senechal, B.; Wang, X.; Purdon, T.; Wang, Y.; Halton, E.; Diamonte, C.; Li, D.; more...
    Journal of Clinical Oncology (2017)

    Fulltext@MSK | Save
  • Development and evaluation of a human single chain variable fragment (scFv) derived BCMA targeted CAR T Cell vector leads to a high objective response rate in patients with advanced MM
    Meeting Abstract

    Smith, E. L.; Mailankody, S.; Ghosh, A.; Masakayan, R.; Staehr, M.; Purdon, T. J.; Halton, E.; Diamonte, C.; Anant, P.; Bernal, Y.; more...
    Blood (2017)

    Fulltext@MSK | Save